Ossium Health
Clinical-stage bioengineering company that recovers, processes, cryopreserves, and banks bone marrow recovered from consented deceased organ donors to provide on‑demand allogeneic grafts and develop cell therapy products. Operates an FDA-registered manufacturing facility and a CLIA-certified laboratory, runs clinical studies and expanded access programs, and partners with organ procurement organizations, transplant centers, and life-science companies.
Industries
Nr. of Employees
medium (51-250)
Ossium Health
Patents
Products
HPC, Marrow
Cryopreserved hematopoietic progenitor cell (marrow-derived) grafts recovered from deceased donor vertebral bodies and banked for on-demand allogeneic transplantation.
GMP selected CD34+ cells
Manufacture and provision of GMP-selected CD34+ hematopoietic stem/progenitor cell products derived from donor marrow for clinical applications and research.
GMP mesenchymal stromal cells (MSCs)
Production of GMP-grade mesenchymal stromal cells derived from donor bone marrow for investigational and therapeutic uses.
Viable bone matrix allograft
A viable bone matrix product derived from vertebral bodies intended for orthopedic repair and reconstruction of musculoskeletal defects.
GMP Selected CD34+ Cells from HPC, Marrow
Ossium’s CD34+ cells are aseptically selected from the bone marrow of vertebral bodies by density gradient and positive immunomagnetic separation, adjusted to a final concentration in buffer containing DMSO for cryopreservation.
RUO Selected CD34+ Cells from HPC, Marrow (1 million cell / vial)
Ossium’s RUO CD34+ cells are aseptically selected from the bone marrow of vertebral bodies by density gradient and positive immunomagnetic separation, adjusted to a final concentration in buffer containing DMSO for cryopreservation.
HPC, Marrow
Cryopreserved hematopoietic progenitor cell (marrow-derived) grafts recovered from deceased donor vertebral bodies and banked for on-demand allogeneic transplantation.
GMP selected CD34+ cells
Manufacture and provision of GMP-selected CD34+ hematopoietic stem/progenitor cell products derived from donor marrow for clinical applications and research.
GMP mesenchymal stromal cells (MSCs)
Production of GMP-grade mesenchymal stromal cells derived from donor bone marrow for investigational and therapeutic uses.
Viable bone matrix allograft
A viable bone matrix product derived from vertebral bodies intended for orthopedic repair and reconstruction of musculoskeletal defects.
GMP Selected CD34+ Cells from HPC, Marrow
Ossium’s CD34+ cells are aseptically selected from the bone marrow of vertebral bodies by density gradient and positive immunomagnetic separation, adjusted to a final concentration in buffer containing DMSO for cryopreservation.
RUO Selected CD34+ Cells from HPC, Marrow (1 million cell / vial)
Ossium’s RUO CD34+ cells are aseptically selected from the bone marrow of vertebral bodies by density gradient and positive immunomagnetic separation, adjusted to a final concentration in buffer containing DMSO for cryopreservation.
Services
An expanded access program providing cryopreserved hematopoietic progenitor cell marrow for patients with urgent or unmet allogeneic transplant needs; clinicians submit requests and products are shipped on-demand.
Onboarding program and operational guidance for organ procurement organizations and recovery professionals to supply vertebral bodies for bone marrow banking.
An expanded access program providing cryopreserved hematopoietic progenitor cell marrow for patients with urgent or unmet allogeneic transplant needs; clinicians submit requests and products are shipped on-demand.
Onboarding program and operational guidance for organ procurement organizations and recovery professionals to supply vertebral bodies for bone marrow banking.
Expertise Areas
- Bone marrow banking and allogeneic transplantation
- Cryopreservation and biobanking process engineering
- GMP cell therapy manufacturing
- Clinical trial management and expanded-access programs
Key Technologies
- Cryopreservation and controlled-rate freezing
- Hematopoietic stem cell processing
- CD34+ selection and characterization
- Mesenchymal stromal cell production
News & Updates
Abstract and poster selected as a Top Poster at AABB 2026 presenting data on post-thaw CD34+ viability, CFU potency, engraftment outcomes, and safety of banked deceased-donor bone marrow.
Congressional visit showcasing manufacturing operations at the Indianapolis production facility and the company’s role in organ donor-derived bone marrow banking.
Publication reporting standardized, centralized GMP manufacturing and cryopreservation validation demonstrating stability, consistency, and clinical performance of cryopreserved deceased-donor bone marrow.
Oral and poster presentations describing first-in-human data and additional clinical experience with cryopreserved deceased-donor bone marrow.
Announcement of $52M Series C financing to grow the bone marrow bank, advance clinical trials, and support product launches including an orthopedic allograft.
Abstract selected for the curated Top Posters Tour at the AABB Annual Meeting highlighting innovations in cellular therapies.
Abstract and poster selected as a Top Poster at AABB 2026 presenting data on post-thaw CD34+ viability, CFU potency, engraftment outcomes, and safety of banked deceased-donor bone marrow.
Congressional visit showcasing manufacturing operations at the Indianapolis production facility and the company’s role in organ donor-derived bone marrow banking.
Publication reporting standardized, centralized GMP manufacturing and cryopreservation validation demonstrating stability, consistency, and clinical performance of cryopreserved deceased-donor bone marrow.
Oral and poster presentations describing first-in-human data and additional clinical experience with cryopreserved deceased-donor bone marrow.
Announcement of $52M Series C financing to grow the bone marrow bank, advance clinical trials, and support product launches including an orthopedic allograft.
Abstract selected for the curated Top Posters Tour at the AABB Annual Meeting highlighting innovations in cellular therapies.